Results

Protalix BioTherapeutics Inc.

05/29/2022 | Press release | Distributed by Public on 05/29/2022 00:56

Safety and efficacy of pegunigalsidase alfa vs agalsidase beta on renal function in Fabry disease - 24-month results from the phase III randomized, double-blind, BALANCE study;[...]